FDA clearance for TearScience thermal pulsation system
TearScience has announced that it has received US Food and Drug Administration (FDA) clearance for its LipiFlowThermal Pulsation System for the treatment of meibomian gland dysfunction (MGD). The clearance enables TearScience to market and sell LipiFlow to eye care physicians in the US. LipiFlow will be available immediately, but on a limited basis in the US through the end of 2011.
Latest Articles
Towards a Unified IOL Classification
The new IOL functional classification needs a strong and unified effort from surgeons, societies, and industry.
The 5 Ws of Post-Presbyopic IOL Enhancement
Fine-tuning refractive outcomes to meet patient expectations.
AI Shows Promise for Meibography Grading
Study demonstrates accuracy in detecting abnormalities and subtle changes in meibomian glands.
Are There Differences Between Male and Female Eyes?
TOGA Session panel underlined the need for more studies on gender differences.
Simulating Laser Vision Correction Outcomes
Individualised planning models could reduce ectasia risk and improve outcomes.
Need to Know: Aberrations, Aberrometry, and Aberropia
Understanding the nomenclature and techniques.
When Is It Time to Remove a Phakic IOL?
Close monitoring of endothelial cell loss in phakic IOL patients and timely explantation may avoid surgical complications.
Delivering Uncompromising Cataract Care
Expert panel considers tips and tricks for cataracts and compromised corneas.
Organising for Success
Professional and personal goals drive practice ownership and operational choices.